• Work With Us
    • Partnerships
      • We offer tailored partnerships to support and transform drug discovery.

        Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

    • Services
      • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

        As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

    • OrganoReady®
      • Our OrganoReady program is made for you when you need defined assays in ADME.

        We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Resources & Support
    • Knowledge Center
      • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

    • Blogs
      • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
    • Case Studies
      • Get inspired by research done by our scientists, partners, and customers around the globe.

    • Webinars & Events
    • Applications
  • About MIMETAS
  • News
  • We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need defined assays in ADME.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Get inspired by peer-reviewed publications, webinars, whitepapers, app notes and more in our knowledge center.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Modelling and prevention of acute kidney injury

Leiden, February 24, 2022 – Scientists from MIMETAS and Astellas introduce a combined human renal proximal tubule/blood vessel-on-a-chip model in the OrganoPlate® 3-lane 40 to study acute kidney injury (AKI) caused by renal ischemia/reperfusion injury (rIRI). This article has just been published in Kidney360.

The kidneys are responsible for removing waste products from our blood, while simultaneously facilitating the reuptake of essential nutrients. This results in a high energy demand, and dependency on supply of oxygen and nutrients through the blood flow. Both disruption (ischemia) and the restart (reperfusion) of the blood flow can cause a loss of function of kidney cells and ultimately lead to AKI. This results in over 13 million yearly diagnoses, where a person’s kidneys suddenly shut down, causing toxins to accumulate in the bloodstream. AKI progression can lead to chronic kidney injury, cardiovascular pathology, and ultimately death.

To study the systemic symptoms of AKI, in vivo animal models are often used. Unfortunately, due to interspecies differences, not all drug candidates that shown efficacy in the animal models translate to efficacious candidates in clinical trials. Similarly, traditional 2D in vitro models fail to recapitulate the kidney structure and function, which makes them unsuited to predict clinical outcomes. Organ-on-a-chip technology offers a physiologically relevant alternative by culturing in vitro models in 3D to mimic the structure and function of the kidney, increasing the predictive value required for drug development and disease research.

In this publication, an advanced kidney model was developed to study rIRI induced AKI. This model is based on a perfused 3D proximal kidney tubule in addition to a 3D perfused blood vessel, cultured from RPTEC and HUVEC cells, respectively. In this model, rIRI could be captured by altering oxygen levels, nutrient availability, and perfusion flow. It was shown that a combination of low oxygen, reduced glucose, and interrupted flow was potent to significantly damage the kidney tubules. Additionally, the damaging effect was amplified upon reperfusion of the tubules and could be alleviated through an adenosine treatment. The robustness and high-throughput capabilities of the model make it a valuable asset to advance pathophysiological research and drug development against AKI.

Go to the publication Sign up for our Newsletter

Cookies

‘May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy

Accept all
Accept selected
Decline all